[HTML] frontiersin.org

[HTML][HTML] Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

F Yang, Y He, N Ge, J Guo, F Yang, S Sun - Frontiers in Immunology, 2024 - frontiersin.org
Introduction Pancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate
among all solid tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS …
相关文章

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

F Yang, Y He, N Ge, J Guo, F Yang… - Frontiers in …, 2024 - pubmed.ncbi.nlm.nih.gov
Introduction Pancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate
among all solid tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS …

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

F Yang, Y He, N Ge, J Guo, S Sun - Frontiers in Immunology, 2023 - europepmc.org
Methods A total of 184 and 412 patients with PDAC from The Cancer Genome Atlas (TCGA)
database and the International Cancer Genome Consortium (ICGC), respectively, were …
[HTML] nih.gov

[HTML][HTML] Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

F Yang, Y He, N Ge, J Guo, F Yang… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Methods A total of 184 and 412 patients with PDAC from The Cancer Genome Atlas (TCGA)
database and the International Cancer Genome Consortium (ICGC), respectively, were …
[PDF] researchgate.net

[PDF][PDF] Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

F Yang, Y He, N Ge, J Guo, F Yang, S Sun - 2024 - researchgate.net
Methods: A total of 184 and 412 patients with PDAC from The Cancer Genome Atlas (TCGA)
database and the International Cancer Genome Consortium (ICGC), respectively, were …

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.

F Yang, Y He, N Ge, J Guo, S Sun - Frontiers in Immunology, 2024 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate among all solid
tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS mutations are …